In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models
Fig 6
(A) LigandRNA score reported for compound families 1 and 2. Pentamidine and Hoechst 33258 reference energies are included as red and grey lines, respectively. (B) Superposition of a pyrido[2,3-d]pyrimidine fragment and the binding hotspots (model B, solution 2) predicted with the druggability analysis. (C) Hypothesized interaction between a pyrido[2,3-d]pyrimidine subunit and a uracil residue.